Department of Clinical and Biological Sciences, San Luigi Gonzaga Teaching Hospital, University of Turin-Second School of Medicine, Reg. Gonzole 10, 10043 Orbassano, Turin, Italy.
World J Gastroenterol. 2011 Apr 14;17(14):1836-9. doi: 10.3748/wjg.v17.i14.1836.
To report our experience of gastrointestinal stromal tumors (GISTs) during the last 29 years.
Thirty two cases of GIST referred to our Institution from the 1st January 1981 to the 10th June 2010 were reviewed. Metastases, recurrence and survival data were collected in relation to age, history, clinical presentation, location, size, resection margins and cellular features.
Mean age was 63.7 years (range, 40-90) and incidence was slightly higher in males (56%). R0 resection was performed in 90.7% of cases, R1 in 6.2% (2 cases) and R2 in 3.1% (one case). Using Fletcher's classification 8/32 (25%) had high risk, 9/32 (28%) intermediate and 15/32 (47%) low risk tumors. Follow-up varied from 1 mo to 29 years, with a median of 8 years; overall survival was 75% (24/32), disease-free survival was 72% and tumor-related mortality was 9.3%. Three patients with high risk GIST were treated with imatinib mesylate: one developed a recurrence after 36 mo, and 2 are free from disease at 41 mo.
Surgical treatment remains the gold standard therapy for resectable GISTs. Pathological and biological features of the neoplasm represent the most important factors predicting the prognosis.
报告我们过去 29 年来胃肠道间质瘤(GIST)的经验。
回顾了 1981 年 1 月 1 日至 2010 年 6 月 10 日期间我院收治的 32 例 GIST 患者。收集了与年龄、病史、临床表现、部位、大小、切缘和细胞特征有关的转移、复发和生存数据。
平均年龄为 63.7 岁(范围为 40-90),男性发病率略高(56%)。90.7%的病例行 R0 切除术,6.2%(2 例)行 R1 切除术,3.1%(1 例)行 R2 切除术。根据 Fletcher 分类,8/32(25%)例为高危,9/32(28%)例为中危,15/32(47%)例为低危肿瘤。随访时间从 1 个月到 29 年不等,中位数为 8 年;总生存率为 75%(24/32),无病生存率为 72%,肿瘤相关死亡率为 9.3%。3 例高危 GIST 患者接受了甲磺酸伊马替尼治疗:1 例在 36 个月后复发,2 例在 41 个月后无疾病。
手术治疗仍然是可切除 GIST 的金标准治疗方法。肿瘤的病理和生物学特征是预测预后的最重要因素。